Form 4 for RMD ResMed|
Accepted 2026-09-10 06:40:28 ET · period of report 2026-09-08 · accession 0000943819-26-000052 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-10 06:40 | 2026-09-08 | RMD | Farrell Michael J. | COB, CEO, Dir | M - OptEx | $146.34 | +4,991 | 471.2K | +1% | +$730.4K |
| DT | 2026-09-10 06:40 | 2026-09-08 | RMD | Farrell Michael J. | COB, CEO, Dir | S - Sale+OE | $222.44 | -4,991 | 466.3K | -1% | -$1.11M |
| DT | 2026-09-10 06:40 | 2026-09-08 | RMD | Farrell Michael J. | COB, CEO, Dir | M - OptEx | $0.00 | -4,991 | 9,984 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2026-09-08 | M | A | 4,991 | $146.34 | 471,247 | D | — | — | (F1) The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. |
| 2 | Common | ResMed Common Stock | 2026-09-08 | S | D | 4,991 | $222.44 | 466,256 | D | — | — | (F1) The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. (F2) This transaction was executed in multiple trades at prices ranging from $220.680 - $225.390. The price reported above reflects the weighted average sale price. |
| 3 | Derivative | ResMed Common Stock Options | 2026-09-08 | M | D | 4,991 | $0.00 | 9,984 | D | $146.34 · 2020-11-11 to 2026-11-21 | 4,991 ResMed Common Stock | (F1) The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. (F3) Represents date options first become exercisable. Options vest 1/3 per year. |